The survey below uses a hypothetical RCT with several pragmatic features. It describes a very inclusive recruitment plan of 'real life' patients-all patients in a health care system with diabetes or leukemia, depending on the scenario-and the use of medical records as sources of outcome, as well as using the clinic itself as the setting for the RCT.]
[All Respondents]
In this next set of questions, we are trying to learn what type of permission is needed from patients when they are asked to participate in different types of medical research.
We will describe one type of research using a hypothetical (pretend) scenario and ask your opinions about it.
[Randomize respondents to 4 even groups]
[Group 1: Low Stakes, Traditional Framing]

Diabetes
Diabetes is a chronic medical condition in which a patient's blood sugar levels are too high. Usual care for patients with diabetes involves blood sugar monitoring, encouraging healthy eating, and sometimes medicines (like insulin). Patients can manage diabetes and live for a long time with these usual care interventions.
Now imagine that there is a commonly available nutritional supplement called MZN. Researchers recently discovered that in animals with diabetes, MZN might help to control the disease. Although people take MZN for other reasons, doctors do not normally talk to their diabetic patients about MZN because no one knows whether it will help lower blood sugar in humans with diabetes. So the researchers want to conduct a study-called a randomized clinical trial-to find out whether taking MZN in addition to usual care lowers blood sugar more than usual care alone.
1. Identify all patients in the healthcare system who have diabetes.
2. Randomize (like flipping a coin) these patients to the control group or the experimental group.
3A. The experimental group will be asked if they are willing to take MZN in addition to usual care as part of the clinical trial. They will be told about the purpose of the trial, the potential consequences of taking MZN, and other details about the clinical trial. They will be free to refuse the MZN.
3B. The control group will continue to receive usual care for diabetes. They will not be told about the MZN clinical trial. But their medical records will be used as data.
4. At the end of the randomized clinical trial, the researchers will compare the average blood sugar levels between the two groups using their medical records. Diabetes is a chronic medical condition in which a patient's blood sugar levels are too high. Usual care for patients with diabetes involves blood sugar monitoring, encouraging healthy eating, and sometimes medicines (like insulin). Patients can manage diabetes and live for a long time with these usual care interventions. Now imagine that there is a commonly available nutritional supplement called MZN. Researchers recently discovered that in animals with diabetes, MZN might help to control the disease. Although people take MZN for other reasons, doctors do not normally talk to their diabetic patients about MZN because no one knows whether it will help lower blood sugar in humans with diabetes. So the researchers want to conduct a study to find out whether taking MZN in addition to usual care lowers blood sugar more than usual care alone.
Prior Permission for Future Use of Medical Records Will Be Obtained
The following study will take place in an academic healthcare system involving only diabetic patients who have already agreed to have their medical records used in future research studies. All research with these medical records is reviewed by an ethics review board, and the records are kept safe and confidential.
Research Proposal
Over the next four screens, we will describe the steps researchers will use to determine if MZN in addition to usual care is better than usual care alone.
2. Randomly select (like flipping a coin) about half of the patients and ask them if they are willing to take MZN in addition to usual care as part of the study. They will be told about the purpose of the research, the potential consequences of taking MZN, and other details about the study. They will be free to refuse the MZN.
3. Everyone else will continue to receive usual care for diabetes. They will not be told about the MZN study. But their medical records will be used as data.
4.
At the end of the study period, the researchers will compare the average blood sugar levels between the two groups using their medical records.
Ethics Review Board
An ethics review board is reviewing the study to decide whether to approve it. Some members of the review board point out that patients who are not selected for MZN will not know that their medical records are being used in the MZN study specifically. Those patients also will not know that other people were randomly offered MZN.
Other members think that those not selected for MZN do not need to know about the MZN study since nothing about their usual care for diabetes will change, and all of the patients already provided permission for the use of their medical records in future research studies. Now we are going to ask you some questions about the MZN study.
Q01b
Will patients who are not offered MZN be told that the MZN study is being conducted?
Yes 2. No
Q02b
Will the patients who are offered MZN have an opportunity to refuse to take MZN?
Yes 2. No
Q03b
Some patients are randomly selected to be offered MZN before any patients are told about the MZN study.
True 2. False
Q04b
Would you recommend to the ethics review board that they approve this study? 
Q07b
In your opinion, how risky is it for the patients to be part of the MZN study overall?
1. Not at all risky 2. 3. 4. 5. 6. 7. Extremely risky
[Group 3: High Stakes, Traditional Framing] Leukemia
Leukemia is an aggressive cancer of the blood cells. Usual treatment for leukemia is chemotherapy and sometimes a bone marrow transplant. Patients may die from leukemia if these treatments do not work. Now imagine that there is a commonly available nutritional supplement called MZN. Researchers recently discovered that in animals with leukemia, MZN might help to treat the cancer. Although people take MZN for other reasons, doctors do not normally talk to their leukemia patients about MZN because no one knows whether it will help improve survival in humans with leukemia. So the researchers want to conduct a study-called a randomized clinical trial-to find out whether taking MZN in addition to usual treatment prolongs the lives of patients with leukemia more than usual treatment alone.
Prior Permission for Future Use of Medical Records Will Be Obtained
The following study will take place in an academic healthcare system involving only leukemia patients who have already agreed to have their medical records used in future research studies. All research with these medical records is reviewed by an ethics review board, and the records are kept safe and confidential.
Research Proposal
Over the next five screens, we will describe the steps researchers will use to conduct a randomized clinical trial of MZN. patients to the control group or the experimental group.
3A. The experimental group will be asked if they are willing to take MZN in addition to usual treatment as part of the clinical trial.
They will be told about the purpose of the trial, the potential consequences of taking MZN, and other details about the clinical trial. They will be free to refuse the MZN.
3B. The control group will continue the usual course of treatment for leukemia. They will not be told about the MZN clinical trial. But their medical records will be used as data.
4. At the end of the randomized clinical trial, the researchers will compare survival rates between the two groups using their medical records.
Ethics Review Board
An ethics review board is reviewing the study to decide whether to approve it.
Some members of the review board point out that patients in the control group will not know that they are participating in the MZN clinical trial. Those patients also will not know that other people were randomized to the experimental group.
Other members think that the control group does not need to know that they are participating in the MZN clinical trial since nothing about their usual treatment for leukemia will change, and all of the patients already provided permission for the use of their medical records in future research studies. Now we are going to ask you some questions about the MZN clinical trial.
Q01c
Will the patients in the control group be told that the MZN study is being conducted?
Yes 2. No
Q02c
Will the patients in the experimental group have an opportunity to refuse to take MZN?
Yes 2. No
Q03c
Patients in the MZN clinical trial are randomized to one of two groups before any of them are told about the MZN clinical trial.
True 2. False
Q04c
Would you recommend to the ethics review board that they approve this study? Now imagine that there is a commonly available nutritional supplement called MZN. Researchers recently discovered that in animals with leukemia, MZN might help to treat the cancer. Although people take MZN for other reasons, doctors do not normally talk to their leukemia patients about MZN because no one knows whether it will help improve survival in humans with leukemia. So the researchers want to conduct a study to find out whether taking MZN in addition to usual treatment prolongs the lives of patients with leukemia more than usual treatment alone.
Prior Permission for Future Use of Medical Records Will Be Obtained
Research Proposal
2. Randomly select (like flipping a coin) about half of the patients and ask them if they are willing to take MZN in addition to usual treatment as part of the study. They will be told about the purpose of the research, the potential consequences of taking MZN, and other details about the study. They will be free to refuse the MZN.
3. Everyone else will continue the usual course of treatment for leukemia. They will not be told about the MZN study. But their medical records will be used as data.
4.
At the end of the study period, the researchers will compare survival rates between the two groups using their medical records.
Ethics Review Board
Some members of the review board point out that patients who are not selected for MZN will not know that their medical records are being used in the MZN study specifically. Those patients also will not know that other people were randomly offered MZN.
Other members think that those not selected for MZN do not need to know about the MZN study since nothing about their usual treatment for leukemia will change, and all of the patients already provided permission for the use of their medical records in future research studies. Now we are going to ask you some questions about the MZN study.
Q01d
Introduction
The GfK Group (formerly Knowledge Networks) is passionate about social science, health, and public policy research. We collaborate closely with client teams throughout the research process, while applying rigor in every step. We specialize in innovative online research that consistently gives leaders in academia, government, and business the confidence to make important decisions. GfK delivers affordable, statistically valid online research through KnowledgePanel® and leverages a variety of other assets, such as world-class advanced analytics, an industry-leading physician panel, an innovative platform for measuring online ad effectiveness, and a research-ready behavioral database of frequent supermarket and drug store shoppers.
GfK has recruited the first online research panel that is representative of the entire U.S. population. Panel members are randomly recruited through probability-based sampling, and households are provided with access to the Internet and hardware if needed.
GfK recruits panel members by using address-based sampling (ABS) methods (previously GfK relied on random-digit dialing [RDD] methods). Once household members are recruited for the panel and assigned to a study sample, they are notified by email for survey taking, or panelists can visit their online member page for survey taking (instead of being contacted by telephone or postal mail). This allows surveys to be fielded quickly and economically. In addition, this approach reduces the burden placed on respondents, since email notification is less intrusive than telephone calls and most respondents find answering online questionnaires more interesting and engaging than being questioned by a telephone interviewer. Furthermore, respondents have the convenience to choose what day and time to complete their assigned survey.
KnowledgePanel Methodology Information
KnowledgePanel is the largest online panel that relies on probability-based sampling techniques for recruitment; hence, it is the largest national sampling frame from which fully representative samples can be generated to produce statistically valid inferences for study populations. Our panel provides samples with the highest level of representativeness available in online research for measurement of public opinions, attitudes, and behaviors. The panel was first developed in 1999 by Knowledge Networks, a GfK company. Panel members are randomly selected so that survey results can properly represent the U.S. population with a measurable level of accuracy, features that are not obtainable from nonprobability panels (for comparisons of results from probability versus nonprobability methods, see Yeager et al., 2011 1 ).
KnowledgePanel's recruitment process was originally based exclusively on a national RDD sampling methodology. In 2009, in light of the growing proportion of cellphone-only households, GfK migrated to an ABS recruitment methodology via the U.S. Postal Service's Delivery Sequence File (DSF). ABS not only improves population coverage, but also provides a more effective means for recruiting hard-to-reach individuals, such as young adults and minorities. Households without Internet connection are provided with a webenabled device and free Internet service.
After initially accepting the invitation to join the panel, participants are asked to complete a short demographic survey (the initial Core Profile Survey); answers to this survey allow efficient panel sampling and weighting for future surveys. Upon completing the Core Profile Survey, participants become active panel members. All panel members are provided privacy and confidentiality protections.
ABS Recruitment
To enhance the DSF-based sampling frame used for address selection, we have various ancillary data appended to each household address, thus facilitating complex stratification plans. 2 Taking advantage of such refinements, quarterly samples are selected using a disproportionate stratified sampling methodology across four strata to address differential attrition rates:
1. Hispanic households with at least one 18 to 24 year-old 2. Remaining Hispanic households 3. Remaining households with at least one 18 to 24 year-old 4. All remaining households
Adults from sampled households are invited to join KnowledgePanel through a series of mailings, including an initial invitation letter, a reminder postcard, and a subsequent followup letter. Moreover, telephone refusal-conversion calls are made to nonresponding households for which a telephone number could be matched to a physical address. Invited households can join the panel by:
 Completing and mailing back a paper form in a postage-paid envelope  Calling a toll-free hotline phone number maintained by GfK  Going to a designated GfK website and completing the recruitment form online
Household Member Recruitment
During the initial recruitment survey, all household members are enumerated. Following enumeration, attempts are made to recruit every household member who is at least 13 years old to participate in KnowledgePanel surveys. For household members aged 13 to 17, consent is collected from the parents or the legal guardian during the initial recruitment interview. No direct communication with teenagers is attempted before obtaining parental consent. While surveys can be conducted with these teens directly, in most instances teen surveys are conducted by first selecting a sample of active members who are parents. This parent route alternative makes it possible to reach a larger sample of teens.
Survey Sampling from KnowledgePanel
Once panel members are recruited and profiled by completing our Core Profile Survey, they become eligible for selection for client surveys. Typically, specific survey samples are based on the equal probability selection method (EPSEM) for general population surveys. Customized stratified random sampling based on "profile" data can also be implemented as required by the study design. Profile data can also be used when a survey calls for prescreening-that is, members are drawn from a subsample of the panel, such as females, Republicans, grocery shoppers, etc. (This can reduce screening costs, particularly for rare subgroups.) In such cases, we take care to ensure that all subsequent survey samples drawn that week are selected in such a way as to result in a sample that remains representative of the panel distributions.
adults fairly closely, barring occasional disparities that may emerge for certain subgroups due to differential attrition.
For selection of general population samples from KnowledgePanel, a patented methodology has been developed that ensures all samples behave as EPSEM samples. Briefly, this methodology starts by weighting the pool of active members to the geodemographic benchmarks secured from the latest March supplement of the U.S. Census Bureau's Current Population Survey (CPS) along several dimensions. Using the resulting weights as measures of size, a probability-proportional-to-size (PPS) procedure is used to select study specific samples. It is the application of this PPS methodology with the imposed size measures that produces fully self-weighing samples from KnowledgePanel, for which each sample member can carry a design weight of unity. Moreover, in instances where a study design requires any form of oversampling of certain subgroups, such departures from an EPSEM design are accounted for by adjusting the design weights in reference to the CPS benchmarks for the population of interest.
Study-Specific Final Weights
Once all survey data have been collected and processed, design weights are adjusted to account for any differential nonresponse that may have occurred. Depending on the specific target population for a given study, geodemographic distributions for the corresponding population are obtained from the CPS, the U.S. Census Bureau's American Community Survey (ACS), or in certain instances from the weighted KnowledgePanel profile data. For this purpose an iterative proportional fitting (raking) procedure is used to produce the final weights. In the final step, calculated weights are examined to identify and, if necessary, trim outliers at the extreme upper and lower tails of the weight distribution. The resulting weights are then scaled to aggregate to the total sample size of all eligible respondents.
The following benchmark distributions were used for the raking adjustment of the design weights for respondents who completed this Government & Academic Omnibus survey:
 Gender (Male/Female)  Age (18-29, 30-44, 45-59, and 60+)  Race/Hispanic Ethnicity (White/Non-Hispanic, Black/Non-Hispanic, Other/Non-Hispanic, 2+ Races/Non-Hispanic, Hispanic)  Education (Less than High School, High School, Some College, Bachelor and beyond)  Census Region (Northeast, Midwest, South, West)  Household Income ($0-$25K, $25-$49,999, $50K-$74,999, $75K-$99,999, $100K-$149,999, $150K+)  Metropolitan Area (Yes, No) 
